Handa Pharmaceuticals, Inc. (TPEX:6620)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
85.50
-1.00 (-1.16%)
Jan 22, 2026, 11:46 AM CST
9.62%
Market Cap13.61B
Revenue (ttm)1.62B
Net Income (ttm)683.16M
Shares Out157.33M
EPS (ttm)4.53
PE Ratio19.09
Forward PEn/a
Dividend1.51 (1.72%)
Ex-Dividend Daten/a
Volume1,000
Average Volume687,215
Open87.10
Previous Close86.50
Day's Range85.20 - 88.20
52-Week Range55.00 - 154.00
Beta0.93
RSI39.91
Earnings DateDec 26, 2025

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis a... [Read more]

Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6620
Full Company Profile

Financial Performance

In 2024, Handa Pharmaceuticals's revenue was 830.67 million, a decrease of -24.92% compared to the previous year's 1.11 billion. Earnings were 472.74 million, a decrease of -34.96%.

Financial Statements